Nektar Therapeutics Aktie
WKN: 165417 / ISIN: US6402681083
03.07.2025 05:25:42
|
Nektar Therapeutics Prices $100 Mln Public Offering Of Common Stock At $23.50 Per Share
(RTTNews) - Nektar Therapeutics (NKTR), a clinical-stage biotech firm specializing in immunotherapy, has priced its underwritten public offering of approximately $100 million in common stock.
The company will issue 4,255,320 shares at $23.50 per share, with gross proceeds expected to be around $100 million before underwriting discounts and offering expenses.
Additionally, underwriters have a 30-day option to purchase up to 638,298 more shares at the same price, excluding underwriting fees. The offering, which includes only Nektar-issued securities, is expected to close on July 2, 2025, subject to customary conditions.
Proceeds from the offering will be used for general corporate purposes, including R&D, clinical development, and manufacturing costs to advance the company's pipeline of drug candidates.
The securities are being offered under an effective shelf registration statement filed with the SEC in March 2025. The final prospectus supplement will be filed with the SEC and made available on www.sec.gov, as well as through Jefferies and Piper Sandler upon request.
Nektar noted the announcement does not constitute an offer or solicitation in any jurisdiction where such actions would be unlawful prior to appropriate registration or qualification.
Wednesday, NKTR closed at $25.53, up 3.82%, and edged up to $25.62 after hours, gaining 0.35% on the NasdaqCM.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
13.06.25 |
NASDAQ Composite Index-Titel Nektar Therapeutics-Aktie: So viel Verlust hätte ein Nektar Therapeutics-Investment von vor 10 Jahren eingebracht (finanzen.at) | |
06.06.25 |
NASDAQ Composite Index-Wert Nektar Therapeutics-Aktie: So viel Verlust wäre bei einem Investment in Nektar Therapeutics von vor 5 Jahren angefallen (finanzen.at) | |
05.06.25 |
Schwache Performance in New York: NASDAQ Composite sackt zum Ende des Donnerstagshandels ab (finanzen.at) | |
05.06.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite liegt nachmittags im Minus (finanzen.at) | |
05.06.25 |
Pluszeichen in New York: NASDAQ Composite legt zu (finanzen.at) | |
05.06.25 |
Börse New York: NASDAQ Composite liegt zum Start des Donnerstagshandels im Minus (finanzen.at) | |
03.06.25 |
Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain (finanzen.at) | |
02.06.25 |
Freundlicher Handel: NASDAQ Composite schließt in der Gewinnzone (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,60 | -3,57% |
|